QH-104

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameQH-104
Drug Alias NameAllogenic B7H3 CAR-γδT cell TherapyAimored B7H3 CAR-γδT cell TherapyAllogenic B7H3-targeting CAR-γδT Cell TherapyQH-104QH-104A
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Chimeric antigen receptor γδT cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy > Chimeric antigen receptor γδT cell therapy
Mechanisms of ActionCD276 antigen modulatorsT lymphocyte replacementsImmunologic cytotoxicity
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumoursCentral Nervous System NeoplasmsOvarian Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Qinghui Liannuo Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesCancer Hospital Of Chinese Academy Of Medical SciencesPeking UniversityBeijing Qinghui Liannuo Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCentral Nervous System NeoplasmsOvarian Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A